Table 2.
Donor | Specificity | TCR Vβ |
# T cell lines/clones tested |
Allo-HLA-C | Allo-HLA-E, -G | Target cell (s) |
Allo-HLA-C, -E, -G cross-reactivity |
---|---|---|---|---|---|---|---|
A | HCMV A2/NLV | 2 | 2 | 2 | 2 | SALs | No |
HCMV A2/NLV | 8 | 3 | 2 | 3 | SALs | No | |
HCMV A2/NLV | 13.1 | 1 | 0 | 1 | SALs | No | |
HCMV A2/NLV | 5.2 | 1 | 0 | 1 | SALs | No | |
HCMV A2/NLV | # | 9 | 0 | 9 | SALs | No | |
A | HCMV B35/IPS | 2 | 1 | 0 | 1 | SALs | No |
HCMV B35/IPS | 3 | 2 | 2 | 2 | SALs | No | |
HCMV B35/IPS | 13.2 | 2 | 1 | 2 | SALs | No | |
HCMV B35/IPS | 22 | 1 | 1 | 1 | SALs | No | |
HCMV B35/IPS | * | 2 | 2 | 2 | SALs | No | |
B | HCMV B35/IPS | 3 | 3 | 2 | 3 | SALs | No |
C | HCMV B35/IPS | 3 | 4 | 2 | 4 | SALs | No |
A | FLU A2/GIL | 17 | 3 | 2 | 3 | SALs | No |
FLU A2/GIL | 17+18 | 1 | 0 | 1 | SALs | No | |
D | FLU A2/GIL | 17 | 4 | 1 | 4 | SALs | No |
B | FLU A2/GIL | # | 3 | 2 | 3 | SALs | No |
E | FLU A2/GIL | # | 2 | 1 | 2 | SALs | No |
F | FLU A2/GIL | # | 1 | 0 | 1 | SALs | No |
F | VZV A2/ALW | # | 1 | 1 | 1 | SALs | No |
G | VZV A2/ALW | # | 1 | 1 | 1 | SALs | No |
H | EBV B35/YPL | 14 | 1 | 1 | 1 | SALs | No |
EBV B35/YPL | 21.3 | 2 | 2 | 2 | SALs | No | |
EBV B35/YPL | * | 1 | 1 | 1 | SALs | No | |
I | EBV A2/GLC (decidua parietalis) | # | 1 | 1 | 1 | SALs | No |
J | EBV B8/FLR | 7 | 2 | 2 | 2 | SALs, EBV-LCLs | No |
K | EBV B8/FLR (4D5) | 3 | 1 | 1 | 1 | SALs, EBV-LCLs, PHA blasts |
HLA-C*01:02 |
EBV B8/FLR | 4 | 2 | 2 | 2 | SALs, EBV-LCLs | No | |
L | HCMV C*0702/CRV | 6 | 1 | 1 | 1 | 721.221, EBV-LCLs | No |
M | HCMV C*0602/TRA | 13 | 2 | 2 | 2 | SALs, EBV-LCLs | No |
HCMV C*0602/TRA (1A3, 7A12, 10C1) | 28 | 2 | 2 | 2 | SALs, EBV-LCLs, PHA blasts | HLA-C*03:02 | |
Summary | |||||||
* The TCR Vβ could not be determined with the TCR Vβ kit used. | Specificities | 9 | |||||
# Not tested. | Donors | 13 | |||||
TCR tested | 21 | ||||||
T cell lines/clones tested against HLA-C, -E, -G | 34 |